XCHO - XenaCare Holdings, Inc. (OTCBB Stock)

[KittyCat]

( I wanted to add this post at the last, but since I can`t seem to delete it, here it is:

I am SOOO sorry - I have not added XCHO to my list of stocks!

Here is a piece of VERY important info:


NPHC is launching Cobroxin with the help of XCHO who will be manufacturing and selling the product because they have the exclusive license, and the marketing facilities, to do so.

The two companies work closely together with XCHO being the marketing arm and NPHC being the scientific arm. Also if you look at Rik Deitsch of NPHC you will see he is also on the board of directors for XCHO.

NPHC doesn't have the capacity to market the product itself. It makes no sense that the market cap of NPHC is currently 20x higher than XCHO.

If NPHC can support a market cap of $50 million based on future sales of cobroxin, then XCHO is way undervalued.

[KittyCat]

XenaCare Holdings Receives Exclusive License to Market & Distribute an FDA Approved Over the Counter Treatment for Chronic PainXenaCare Holdings Receives Exclusive License to Market & Distribute an FDA Approved Over the Counter Treatment for Chronic Pain

Date : 05/26/2009 @ 9:00AM
Source : Business Wire
Stock : XenaCare (XCHO)
Quote : 0.09 0.015 (20.00%) @ 7:58AM

XenaCare Holdings Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products has announced today that it has received the exclusive U.S. license to market and distribute an FDA approved homeopathic treatment for chronic pain.

“We are extremely enthusiastic about this product, as it represents one of the first non-narcotic treatments for chronic pain,” explained Frank Rizzo, Chief Executive Officer of XenaCare Holdings. “As we move towards our August launch, we plan to release full details about the product as well as its potential to compete effectively with current opiate-based drugs available on the market,” he added.

Chronic pain currently affects more than 50 million people throughout the United States. Each year, more than 25 million additional people in the U.S. experience acute pain as a result of injury or surgery. In 2005, U.S. sales of pain management products, including prescription and non-prescription pain drugs, totaled approximately $20.4 billion.

Recently, XenaCare announced the launch of the SunPill, a dietary supplement that helps the skin protect itself from the harmful rays of the sun. The SunPill is currently available at RiteAid, CVS.com Drugstore.com and Amazon.com and many other Mass Retailers.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare Holding’s ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Receiving an exclusive marketing and distribution license for the treatment of chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[KittyCat]

XenaCare Holdings’ Pain Reliever, Cobroxin, Wins “Best New Product” Award at the Efficient Collaborative Retail Marketing Conference

Date : 08/17/2009 @ 9:00AM
Source : Business Wire
Stock : XenaCare Holdings, Inc. (XCHO)
Quote : 0.09 0.015 (20.00%) @ 7:58AM

XenaCare Holdings’ Pain Reliever, Cobroxin, Wins “Best New Product” Award at the Efficient Collaborative Retail Marketing Conference

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products has announced today that its stage 2 pain reliever, Cobroxin, has won the award for “Best New Product” at the recent Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida.

“It is an honor to have Cobroxin chosen as the best new product at ECRM,” commented Frank Rizzo, President of XenaCare Holdings, Inc. “This award, which was selected by fellow conference attendees, including representatives from many of the major national retailers, supports our belief that Cobroxin will soon become the preferred alternative to current opiate and acetaminophen-based analgesics,” he concluded.

Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license for marketing and distributing Cobroxin within the United States.

As an added prize for winning the award, XenaCare Holdings will also receive a full page advertisement in an upcoming issue of Drug Store News, a placement reaching over 31,000 subscribers.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. Its clinical products include XenaCor, which lowers serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.

Xena Care Holdings

Cobroxin™ for Chronic Pain

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The award given to XenaCare at ECRM should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[KittyCat]

Nutra Pharma Announces Licensing Agreement with XenaCare Holdings to Market & Distribute Cobroxin, a Treatment for Chronic Pain

Date : 08/26/2009 @ 9:00AM
Source : Business Wire
Stock : (XCHO)
Quote : 0.09 0.015 (20.00%) @ 7:58AM

Nutra Pharma Announces Licensing Agreement with XenaCare Holdings to Market & Distribute Cobroxin, a Treatment for Chronic Pain

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

“We are pleased to be working with XenaCare as our exclusive US marketing and distribution licensee for Cobroxin,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “For the past several months, XenaCare has continued to commit significant time, industry expertise and financial resources towards the launch of Cobroxin. We look forward to working closely with them as they complete the initial roll-out of Cobroxin to retailers across the country,” he added.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.

Additional benefits to Cobroxin include:

All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
More Potent than Morphine
Long Lasting
“Cobroxin is a unique pain reliever that we believe can help improve the lives of the millions of Americans who are actively seeking a safer and more effective alternative for treating chronic pain,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “We have already committed millions of dollars and industry resources towards the launch of Cobroxin and will continue to do so as we successfully introduce Cobroxin through retailers this fall,” he concluded.

On Monday, Nutra Pharma announced that it had completed submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA). This submission was the final step required to begin selling Cobroxin.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Nutra Pharma Corp. (NPC) :: Drug Discovery and Medical Devices

Cobroxin™ for Chronic Pain

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completing the agreement with XenaCare Holdings for marketing and distributing Cobroxin throughout the United States should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[greencat]

XCHO Chart

[KittyCat]

Nutra Pharma’s Recently Launched Pain Reliever, Cobroxin, Wins “Best New Product” Award at Retailing Conference

Date : 08/31/2009 @ 9:00AM
Source : Business Wire
Stock : (XCHO)
Quote : 0.09 0.015 (20.00%) @ 7:58AM

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

“Winning this award is an exciting achievement for Nutra Pharma, as it reflects the significant amount of positive response we have received from retailers who are looking to offer their customers a safe and effective alternative to current pain relievers,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “As we begin introducing Cobroxin through retailers this fall, we plan to continue our efforts educating both retailers and consumers about Cobroxin’s unique analgesic properties, which do not rely on opiates or acetaminophen for its pain relieving effects,” he concluded.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.

Additional benefits to Cobroxin include:

All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
More Potent than Morphine
Long Lasting
Recently, Nutra Pharma announced a licensing agreement that grants XenaCare Holdings (OTCBB: XCHO) ongoing exclusive marketing and distribution rights for Cobroxin within the United States in return for meeting specific minimum performance requirements. In addition, the Company also announced successful submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA), the final step required to begin selling Cobroxin.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Nutra Pharma Corp. (NPC) :: Drug Discovery and Medical Devices

Cobroxin™ for Chronic Pain

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Having Cobroxin selected as the “Best New Product” at ECRM should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[KittyCat]

In other words, NPHC owns the drug formula, and XCHO will be the exclusive company that manufactures it.

And I have noticed that when XCHO goes up, NPHC usually follows.

October is the forecast launch date for Cobroxin.

[KittyCat]

Down 11% EOD today.

[KittyCat]

From MarketWire: 09/04/09

XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.

“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.

Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. Its clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.

Xena Care Holdings

Cobroxin™ for Chronic Pain

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the Cobroxin national print advertising campaign should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[KittyCat]

Closed up 6% today. And I added to my position.